Drug Trial Radar · NCT07024615
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Oct 16, 2025
Primary completion
Jan 31, 2028
Study completion Jan 31, 2028
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jun 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Some people with pancreatic ductal cancer (PDAC) have a protein called Claudin 18.2 (CLDN18.2) in their tumor. ASP2138 is thought to work by binding to CLDN18.2 and a protein on a type of immune cell called a T-cell. The T-cell "tells" the immune system to attack the tumor. This study is for people with resectable PDAC. Resectable means that the tumor can be removed by surgery. In this study, adults with resectable PDAC will receive an ASP2138 injection just below the skin (subcutaneous) 2 weeks before surgery. After surgery, they will be given standard chemotherapy treatments chosen by their study doctor. These include mFOLFIRINOX, gemcitabine with nab-paclitaxel, or gemcitabine with capecitabine. People will receive chemotherapy treatment for up to 6 months, or until their cancer gets worse, they cannot tolerate the chemotherapy, or they or their study doctor thinks they should stop chemotherapy. People will have a final clinic visit about a month after finishing chemotherapy for health checks.
Conditions
- Pancreatic Ductal Adenocarcinoma
Interventions
ASP2138Drug
Subcutaneously
OxaliplatinDrug
Injection
LeucovorinDrug
Injection
5-FUDrug
Injection
IrinotecanDrug
Injection
GemcitabineDrug
Intravenously
Nab-paclitaxelDrug
Intravenously
CapecitabineDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse Events (AEs)Time frame: Up to 11.5 months
- Number of participants with Serious Adverse Events (SAEs)Time frame: Up to 11.5 months
- Number of participants with laboratory value abnormalities and/or AEsTime frame: Up to 11.5 months
- Number of participants with vital signs abnormalities and/or AEsTime frame: Up to 11.5 months
- Number of participants with 12-lead electrocardiogram (ECG) abnormalities and/or AEsTime frame: Up to 10.5 months
- Number of participants with physical examinations (PEs) abnormalities and/or AEsTime frame: Up to 11.5 months
- Number of participants at each grade of Eastern Cooperative Oncology Group (ECOG) performance status scoreTime frame: Up to 11.5 months
- Number of participants with ASP2138-related surgery delays (≥ 7 days)Time frame: Up to 12 weeks after the end of neoadjuvant treatment
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Duke University Medical Center - Duke Cancer Center
Durham, North Carolina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.